Medically reviewed by Jay N. Yepuri, MD Biliary colic is abdominal pain that develops due to a blockage in the bile ducts, ...

Daiichi Sankyo has finalised the acquisition of intellectual property rights for gatipotuzumab, an anti-tumour-associated ...

Biliary tract disease describes any disease that affects the biliary tract the gall bladder, bile ducts and accompanying structures. Examples include primary sclerosing cholangitis, secondary ...

Eisai has filed for approval in Japan for tasurgratinib, its small-molecule fibroblast growth factor (FGF) receptor inhibitor, as a treatment for biliary tract cancers with FGFR2 gene fusion ...

Oppenheimer initiated coverage of Compugen (CGEN) with an Outperform rating and $4 price target. With a sole oncology focus, Compugen is ...

Top-line Phase 2/3 data readout for CTX-009, now named tovecimig (a DLL4 x VEGF-A bispecific), in patients with biliary tract cancer (BTC) is on ...

Ezabenlimab is under clinical development by Boehringer Ingelheim International and currently in Phase II for Metastatic Biliary Tract Cancer.

Japanese drugmaker Daiichi Sankyo announced that it will pay Glycotope GmbH $132.5 million to acquire intellectual property ...

Eisai has launched its new therapy for biliary tract cancer (BTC) Tasfygo in Japan, the first world market for the drug. Tasfygo (tasurgratinib succinate; formerly E7090), a small-molecule ...